3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
10
Neoplasms
5
Carcinoma, Non-Small-Cell Lung
4
Pain, Postoperative
3
Neurotoxicity Syndromes
3
Melanoma
3
Leukemia, Myeloid, Acute
3
Brain Neoplasms
3
Recurrence
2
Ovarian Neoplasms
2
Hemorrhage
2
Chronic Pain
2
Agnosia
2
Vulvodynia
1
Uterine Cervical Neoplasms
1
Stomatitis
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Radiodermatitis
1
Radiation Injuries
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Peripheral Nervous System Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Parathyroid Neoplasms
1
Papillomavirus Infections
1
Pancreatic Neoplasms
1
Interventions
human papillomavirus vaccine, L1 type 16, 18
22
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
15
Papillomavirus Vaccines
9
Vaccines
6
Blood Specimen Collection
4
Watchful Waiting
2
Vaccines, Synthetic
2
Light Coagulation
2
Hepatitis A Vaccines
2
Engerix-B
2
lime
1
halofantrine
1
Sodium Chloride
1
Radiotherapy, Intensity-Modulated
1
Pentetic Acid
1
Olive Oil
1
Observation
1
Measles-Mumps-Rubella Vaccine
1
Laser Therapy
1
Injections
1
Imiquimod
1
Human Papillomavirus DNA Tests
1
Fluorouracil
1
Diphtheria-Tetanus-acellular Pertussis Vaccines
1
DTPa-HBV-IPV combined vaccine
1
Colposcopy
1
Clinical Protocols
1
Cisplatin
1
Circumcision, Male
1
Chorionic Villi Sampling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Papillomavirus Infections
×
Sodium Chloride
×
Clear all
NCT04199689
2025-03-25
V503-049
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
6,033 enrolled